Researchers developed 3D-printed scaffold models to improve glioblastoma drug screening, enabling more physiologically relevant tumor architectures than traditional 2D cultures. The platform, described in Annals of Biomedical Engineering, aims to capture tumor heterogeneity and microenvironmental constraints to yield more predictive preclinical readouts. Developers of oncology discovery programs may adopt such scaffolds to triage candidates earlier and reduce costly late-stage failures.